INTRODUCTION
Micro(mi)RNAs are small, noncoding RNAs, 19-24 nucleotides in length, that negatively regulate expression of multiple genes either by inducing translational silencing or by causing degradation of the mRNA of the targeted gene (Bartel, 2009) . It has been firmly established that miRNAs regulate many key cellular processes such as cell growth, differentiation, and death (Schickel et al., 2008) . Recently, we and others identified the miR-200 family of miRNAs (miR-200a, 200b, 200c, 141, and 429) as both fundamental markers and powerful regulators of the process of epithelial-mesenchymal-transition (EMT) (Gregory et al., 2008; Park et al., 2008) . miR-200 maintains the epithelial phenotype of tissues by suppressing expression of the EMT-inducing transcription factors ZEB1 and ZEB2 (Christoffersen et al., 2007; Gregory et al., 2008; Hurteau et al., 2007; Park et al., 2008) . The repression of E-cadherin by ZEB1 and ZEB2 is characterized by a full-scale shift in phenotype indicative of EMT. A key step in the progression of carcinomas is the loss of an epithelial phenotype and the acquisition of mesenchymal characteristics in a manner highly reminiscent of EMT. The process of EMT is reversible, and a mesenchymal-epithelialtransition (MET) is found during metastases when tumor cells may become partially re-epithelialized (Savagner, 2001) . Consistent with miR-200 being involved in the process of EMT and MET, it has been reported for a number of human cancers that, early during malignant transformation, members of the miR-200 family are downregulated but are subsequently upregulated in advanced stages of cancer (Peter, 2009) .
Tumor progression is a multistep process during which cancer cells undergo a number of changes. These changes include acquisition of mutations in tumor suppressor pathways and in oncogenes (Hanahan and Weinberg, 2000) . In addition, cells become more and more resistant to apoptosis, and as a result, refractory to therapy. One apoptosis pathway that is affected by these changes is the pathway activated by the death receptor, CD95 (Fas/APO-1). It is well established that cancer cells lose sensitivity to CD95-mediated apoptosis either through acquisition of mutations in CD95, downregulation of CD95, or upregulation of antiapoptotic proteins (Peter et al., 2005 (Peter et al., , 2007 . CD95 induces apoptosis by forming a death-inducing signaling complex (DISC) at the receptor that contains FADD, caspase-8/10, and the caspase-8 regulator, c-FLIP (Peter and Krammer, 2003 ). An apoptosis inhibitor that affects CD95 signaling by regulating surface expression of CD95 is Fas-associated phosphatase-1 (FAP-1, also known as PTPN13, PTPL1, or PTP-BAS) (Sato et al., 1995) . FAP-1 has been linked to resistance to apoptosis mediated by CD95 in many human cancers, and an inverse correlation between sensitivity to CD95-mediated apoptosis and the expression of FAP-1 is seen in several tumor types (Elnemr et al., 2001; Foehr et al., 2005; Ivanov et al., 2003; Lee et al., 1999 Lee et al., , 2001 Li et al., 2000; Meinhold-Heerlein et al., 2001; Myc et al., 1999; Nakai et al., 2000; Ungefroren et al., 2001; Wieckowski et al., 2007) .
We previously reported that among the 60 cell lines maintained by the National Cancer Institute (NCI60) cell lines representing early stages of cancer progression (type II tumor cells, which die through a mitochondria-dependent pathway) are more sensitive to CD95 ligand when compared to cell lines that have characteristics of later stages (type I tumor cells, which die without mitochondrial involvement). This provided a model for the changes in CD95 signaling that occur during tumor progression (Algeciras-Schimnich et al., 2003) . We subsequently identified miR-200 to be more highly expressed in early/epithelial cancer cells . We now report that miR-200 increases apoptosis sensitivity of cancer cells through targeting the apoptosis inhibitor, FAP-1. Our data provide a mechanistic explanation for how sensitivity of cancer cells to CD95-mediated apoptosis is lost early during neoplastic transformation.
RESULTS AND DISCUSSION
We previously noted that cells with properties of early cancers (type II cells) had an epithelial phenotype, whereas cells resembling more advanced cancer (type I cells) had a more mesenchymal phenotype (Algeciras-Schimnich et al., 2003) . Because cancer cells lose apoptosis sensitivity during tumor progression including sensitivity to CD95-mediated apoptosis, we determined if changes in miR-200 levels affected CD95 signaling. miR-200c was introduced stably into CAKI-1 and HeyA8 cells, or transiently into ACHN cells. These three cell lines with different levels of sensitivity to CD95-mediated apoptosis possess mesenchymal features. Morphological changes consistent with acquisition of a more epithelial phenotype were noted in all three cell lines treated with miR-200c ( Figure 1A ). In addition, the miR-200c-treated cells showed increased sensitivity to and S1 ), or with anti-APO-1 plus protein A (to crosslink anti-APO-1), or with a leucine-zipper tagged CD95L (LzCD95L), which mimics membrane-bound CD95 ligand in its activity ( Figure S1 ). This enhancement of CD95-mediated apoptosis was also seen when cells were treated with anti-APO-1 in the presence of cycloheximide, suggesting that miR-200 targets a preexisting protein that may affect the CD95 signaling pathway ( Figures 1C and  S1 ). In a converse experiment, when the concentration of miR-200 was reduced in HCT116 cells (which have an epithelial phenotype and express high miR-200), using an inhibitor that targets all 5 miR-200 family members (LNA200, see Park et al. [2008] ), cells became more resistant to apoptosis induction ( Figure 1B ) (Algeciras-Schimnich et al., 2003; Park et al., 2008) .
The changes in apoptosis sensitivity accompanying altered miR-200 expression in most of these cell lines were limited to induction of the extrinsic apoptosis pathway and were not due to a general increase in apoptosis sensitivity, as indicated by the fact that staurosporine treatment, which activates the intrinsic apoptosis pathway, did not lead to significant changes in cell death in these cells ( Figure 1D ). In summary, in different cell lines sensitive to CD95-mediated apoptosis, changing miR-200 levels resulted in altered apoptosis sensitivity, thereby identifying miR-200 as a positive regulator of CD95-mediated apoptosis.
We searched the list of conserved genes predicted to be miR-200 targets using TargetScan 4.2 (http://www.targetscan. org) for known regulators of CD95-mediated apoptosis and identified FAP-1, a known inhibitor of CD95-mediated apoptosis, as a putative target. FAP-1 was a good candidate to cause the observed effects because it has been shown to directly regulate CD95-mediated apoptosis by binding to CD95 (Yanagisawa et al., 1997) and by regulating trafficking of CD95 to the cell surface (Foehr et al., 2005; Ivanov et al., 2003 Ivanov et al., , 2006 . The 3 0 UTR of FAP-1 mRNA contains a conserved miR-200bc/429 target sequence ( Figure 2A ). This result predicted that FAP-1 would be predominantly expressed in mesenchymal cells. This could be confirmed by comparing FAP-1 protein expression in the epithelial cell lines with its expression in the mesenchymal cell lines among the NCI60 cells we recently described (Figure 2B ). The lung cancer cell line H322M was the only outlier among the epithelial cell lines. Sequence and PCR analyses demonstrated that the miR-200c seed match in the 3 0 UTR of FAP-1 mRNA in the H322M cell line is unmutated, and the 3 0 UTR is attached to the open reading frame of FAP-1 (data not shown), suggesting that an unknown mechanism prevents FAP-1 from being targeted by miR-200 in this cell line. Expanding the analysis to the entire set of NCI60 cells we found a significant correlation between FAP-1 expression and the expression of three classical markers of mesenchymal cells: Vimentin, Fibronectin 1, and N-Cadherin ( Figures S2A and  S2B ). In addition, a cell line-by-cell line inverse correlation of expression of FAP-1 protein and miR-200c was detected (Figure 2C) . No correlation was found between FAP-1 and let-7d ( Figure 2D ). The data strongly suggested that FAP-1 is a protein that is predominantly expressed in mesenchymal cells and which is under control of miR-200c. To determine if FAP-1 also plays a role in maintaining mesenchymal cells, we stably knocked down FAP-1 expression using lentiviral shRNAs, and monitored expression of a number of epithelial and mesenchymal markers. Two different FAP-1-specific shRNAs (2 and 3) efficiently knocked down FAP-1 expression ( Figure 2E ). Interestingly, by reducing the expression of FAP-1 we noticed a modest but reproducible upregulation of E-cadherin mRNA and protein (Figures 2E and 2F) suggesting that FAP-1 is not only expressed in mesenchymal cells, but also contributes to the mesenchymal state. Consistent with FAP-1 being a downstream effector of miR-200, reduction in FAP-1 expression did not affect the expression of EMT regulators, ZEB1, ZEB2, Snail, or Twist, or of miR-200c ( Figure S2C ).
While we found a strong inverse correlation between miR200c and FAP-1 expression in the NCI60 cells, the only way to confirm a miRNA target is to observe an inverse change in protein expression when the level of the miRNA is altered and to perform a luciferase reporter assay that compares wild-type (WT) and mutated (mut) 3 0 UTR target sites. First, we performed Western blot analysis of FAP-1-expressing cell lines transiently transfected with pre-miR-200c, or stably expressing miR-200c ( Figure 3A) . In each case the activity of miR-200c was documented by upregulation of E-cadherin, and FAP-1 expression was reduced. Conversely, the inhibition of endogenous miR-200 in HCT116 cells with anti-miR LNA200 led to an increase in FAP-1 and a decrease in E-cadherin expression ( Figure 3A Figure 3E ). Therefore, FAP-1 is a target of miR200c, and regulation of FAP-1 is due to translational repression and not mRNA degradation.
Molecular Cell miR-200 Targets FAP-1
The fact that miR-200c is likely to regulate many targets prompted us to determine the relevance of FAP-1 for the resistance to CD95-mediated apoptosis. The only way to test this is to inhibit miR-200, which should cause upregulation of FAP-1 and increased resistance to CD95-mediated apoptosis. The subsequent knockdown of FAP-1 should allow assessment of the effect and contribution of endogenous FAP-1 and endogenous miR-200 on sensitivity to CD95-mediated apoptosis. As was shown in Figure 2E efficient knockdown of FAP-1 could be accomplished using lentivirus shRNAs. To determine the contribution of FAP-1 to the miR-200-induced changes in sensitivity to CD95-mediated apoptosis, HCT116 cells were transfected with LNA200 which resulted in an increase in FAP-1 protein expression, a reduction of sensitivity to CD95-mediated apoptosis, an increase in endogenous ZEB1 mRNA and protein and ZEB2 mRNA, and a reduction in E-cadherin mRNA and protein ( Figures 4A and 4B) . These same cells with knockeddown FAP-1, however, regained the apoptosis sensitivity of the parental HCT116 cells demonstrating that the increase in FAP-1 protein that we observed after inhibition of miR-200 was FAP-1 has been reported to directly bind to CD95-rendering cells resistant to CD95-mediated apoptosis (Sato et al., 1995; Yanagisawa et al., 1997) , likely by dephosphorylating CD95 on Tyr291-a site important for the receptor to internalize and to signal apoptosis (Foehr et al., 2005; Ivanov et al., 2003 Ivanov et al., , 2006 Lee et al., 2006; Spanos et al., 2008; Zhu et al., 2008) . We previously demonstrated that strong DISC formation requires that CD95 be internalized (Lee et al., 2006) . To test whether miR-200 affects sensitivity to CD95-mediated apoptosis by either inhibiting or promoting formation of the DISC, we analyzed CAKI-1 cells, stably expressing miR-200c, and HCT116 cells, transfected with LNA200 ( Figures S3A and S3B) . In CAKI-I cells DISC formation is prominent because it predominantly forms after internalization of CD95 on endosomes (Lee et al., 2006) . In contrast, in HCT116 cells, which do not efficiently internalize CD95, DISC formation is not detectable by Western blotting (Algeciras-Schimnich et al., 2003) . Neither elevation nor reduction of miR-200 levels had a significant impact on DISC formation in either of the two cell lines, suggesting that FAP-1 does not act by interfering with DISC formation. While this result may seem to be in contradiction to the observed change in sensitivity to CD95-mediated apoptosis, it is consistent with our previous analyses that demonstrated that the efficiency of the formation of the DISC does not correlate with the sensitivity of cells to CD95-mediated apoptosis (Algeciras-Schimnich et al., 2003) .
A careful analysis of CD95 surface expression using flow cytometry revealed that in three out of four cell lines expressing exogenous miR-200c, surface CD95 levels were significantly increased ( Figure 4C ). In HeyA8 cells we also observed a trend that was not statistically significant probably because these cells already express very high levels of CD95. In contrast, in LNA200-treated HCT116 cells CD95 surface levels were reduced. The data are consistent with miR-200c targeting FAP-1, which then affects CD95 surface expression. The change in CD95 surface expression did not translate into a change in the formation of the DISC, which is consistent with the fact that even high CD95-expressing epithelial cells barely form a DISC (AlgecirasSchimnich et al., 2003; Lee et al., 2006) .
Because regulation of CD95-mediated apoptosis sensitivity by miR-200 may occur downstream of the formation of the CD95 DISC, we tested whether miR-200c expression would sensitize cells to apoptosis mediated by other death receptors ( Figure S3C ). When miR-200c was highly overexpressed, CAKI-1 and ACHN cells were found to be more sensitive to TRAIL-induced apoptosis, and CAKI-1 cells were also more sensitive to TNFa-induced apoptosis suggesting that the activity of miR-200c may not be limited to CD95 signaling. However, when endogenous miR-200 was inhibited in HCT116 cells, which rendered these cells less sensitive to CD95-mediated apoptosis, apoptosis sensitivity to either TRAIL or TNFa was not significantly affected ( Figure S3D ). This was confirmed in cells stably expressing a lentiviral antimiR against miR-200 (data not shown).
In summary, we report that miR-200c affects sensitivity to CD95-mediated apoptosis, and have identified and validated FAP-1 as a miR-200 target that regulates CD95-mediated apoptotic signaling in tumor cells. We have determined that EMT induction and miR-200c affect sensitivity of tumor cells to CD95-mediated apoptosis. Loss of apoptosis sensitivity is one of the hallmarks of cancer (Hanahan and Weinberg, 2000) , and miR-200, which is lost during cancer progression, was expected to regulate this. Our data provide a molecular mechanism that explains how miR-200c regulates sensitivity of tumor cells to CD95-mediated apoptosis. Loss of miR-200 causes an increase in FAP-1 expression and a reduction in CD95 surface expression. Although we did not find an effect of miR-200 on sensitivity of cells to staurosporine, a classical activator of the intrinsic apoptosis pathway, loss of miR-200 has recently been reported to render tumor cells resistant to chemotherapeutic drugs including tubulin-disrupting compounds such as paclitaxel. class III b-tubulin (TUBB3) was identified as another miR-200 target regulating this activity (Cochrane et al., 2009) . Therefore, the EMT regulator miR-200 likely regulates apoptosis sensitivity of cancer cells in multiple ways. Future studies will be aimed at identifying other components of the apoptosis machinery that are targeted by miR-200.
EXPERIMENTAL PROCEDURES
Details regarding cell lines and reagents, cell death assays, Western Blotting, PCR, immunostaining, CD95 DISC analysis, and data analysis are provided in the Supplemental Information . 
Transfections and Luciferase Assays
Transient miRNA expressing cells were generated by following the siPORT NeoFX manufacturer's protocol using 150,000 cells and 50 nM of the appropriate miRNA or scrambled control. All pre-miRNAs were supplied from Applied Biosystems. Serial transiently transfected cells were generated following the same transfection protocol repeated every 72 hr. HCT116 cells were serially transfected with a locked nucleic acid (LNA) based inhibitor to miR-200 (LNA200) , or with scrambled LNA control oligonucleotide (Exiqon) every 3 days for up to 21 days (7 transfections) following the siPORT NeoFX protocol for 150,000 cells. In some experiments, HCT116 cells were infected with lentivirus PLKO-control shRNA or PLKO-FAP-1 shRNA (Sigma Aldrich) and were selected with medium containing 2 mg/ml puromycin for 2 weeks. After selection cells were serially transfected seven times with scrambled LNA or LNA-200 oligonucleotides. Luciferase assays were performed on cells seeded in a 48-well plate (2.5 3 10 4 cells/well) 1 day prior to transfection. Cells were transfected with either psiCHECK 3 0 UTR FAP-1 WT or psiCHECK 3 0 UTR FAP-1 mut, along with either Pre-miR-200c or negative control 2 precursor miRNA, using Lipofectamine 2000 (Invitrogen). After 48 hr cells were lysed and Renilla Luciferase activity was determined according to the manufacturer's instructions (Promega). All experiments were performed in triplicate and normalized to the activity of the internal control Firefly Luciferase gene contained within the psiCHECK-2 vector.
SUPPLEMENTAL INFORMATION
Supplemental data include three figures, Supplemental Experimental Procedures, and Supplemental References and can be found with this article online at doi:10.1016/j.molcel.2010.05.018.
